866-997-4948(US-Canada Toll Free)

Escherichia coli Infections - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 165 Pages

Escherichia coli Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections Pipeline Review, H2 2016, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.

Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 31 and 24 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 14 molecules, respectively.Escherichia coli Infections.

Escherichia coli Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Escherichia coli Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Escherichia coli Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Escherichia coli Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Escherichia coli Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Escherichia coli Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Escherichia coli Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Escherichia coli Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Escherichia coli Infections Overview 9
Therapeutics Development 10
Pipeline Products for Escherichia coli Infections - Overview 10
Pipeline Products for Escherichia coli Infections - Comparative Analysis 11
Escherichia coli Infections - Therapeutics under Development by Companies 12
Escherichia coli Infections - Therapeutics under Investigation by Universities/Institutes 14
Escherichia coli Infections - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Escherichia coli Infections - Products under Development by Companies 18
Escherichia coli Infections - Products under Investigation by Universities/Institutes 21
Escherichia coli Infections - Companies Involved in Therapeutics Development 22
Adenium Biotech ApS 22
Arsanis, Inc. 23
AstraZeneca Plc 24
AvidBiotics Corp 25
Cellceutix Corp 26
Debiopharm International SA 27
Emergent BioSolutions Inc 28
F. Hoffmann-La Roche Ltd 29
GangaGen Inc 30
Hsiri Therapeutics LLC 31
Johnson & Johnson 32
Melinta Therapeutics Inc 33
Merck & Co Inc 34
Microbiotix Inc 35
Nabriva Therapeutics AG 36
Navigen Pharmaceuticals, Inc. 37
Nosopharm SAS 38
Novabiotics Ltd 39
Omnia Molecular Ltd 40
Paratek Pharmaceuticals Inc 41
Pherecydes Pharma SA 42
Phico Therapeutics Ltd 43
Procarta Biosystems Limited 44
Sealife PHARMA GMBH 45
Sequoia Sciences Inc 46
Soligenix Inc 47
Syntiron LLC 48
Tetraphase Pharmaceuticals Inc 49
Varinel Inc 50
Escherichia coli Infections - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Target 52
Assessment by Mechanism of Action 54
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 60
A-3APO - Drug Profile 60
AA-139 - Drug Profile 61
AM-8722 - Drug Profile 62
ASN-4 - Drug Profile 63
AvR2-V10 - Drug Profile 64
BC-7634 - Drug Profile 66
BC-9074 - Drug Profile 67
BC-9529 - Drug Profile 68
BC-9563 - Drug Profile 69
BIZ-20131 - Drug Profile 70
BIZ-20132 - Drug Profile 71
BIZ-20133 - Drug Profile 72
CA-824 - Drug Profile 73
CC-1807 - Drug Profile 74
Debio-1454 - Drug Profile 75
Drugs for Bacterial Infections - Drug Profile 76
dusquetide - Drug Profile 77
Escherichia coli (whole cell) vaccine - Drug Profile 82
Escherichia coli vaccine - Drug Profile 83
Escherichia coli vaccine - Drug Profile 84
ETEC [strain B7A] vaccine - Drug Profile 85
ETEC vaccine - Drug Profile 86
EV-035 - Drug Profile 87
GN-4474 - Drug Profile 89
GNEG SNARE - Drug Profile 90
HT-07 - Drug Profile 91
INX-201 - Drug Profile 92
JNJ-63871860 - Drug Profile 93
MBX-2319 - Drug Profile 95
MDN-0057 - Drug Profile 96
mirandamycin - Drug Profile 98
NBTI-5463 - Drug Profile 99
NOSO-95179 - Drug Profile 100
NP-432 - Drug Profile 101
omadacycline tosylate - Drug Profile 102
Onc-72 - Drug Profile 108
P-100031 - Drug Profile 109
Peptides for Infectious Diseases - Drug Profile 110
PMX-100 - Drug Profile 111
PMX-1091 - Drug Profile 112
PMX-1142 - Drug Profile 113
PMX-1241 - Drug Profile 114
PMX-1278 - Drug Profile 115
PMX-1363 - Drug Profile 116
PMX-1405 - Drug Profile 117
PMX-223 - Drug Profile 118
PMX-229 - Drug Profile 119
PMX-247 - Drug Profile 120
PMX-633 - Drug Profile 121
PMX-668 - Drug Profile 122
PMX-693 - Drug Profile 123
PMX-843 - Drug Profile 124
PP-0121 - Drug Profile 125
Proteins for Infectious Diseases - Drug Profile 127
PT-5 - Drug Profile 128
Recombinant Protein for Escherichia Coli Infections - Drug Profile 129
RX-05 - Drug Profile 130
RXP-873 - Drug Profile 131
SE-1 - Drug Profile 132
Shigetec - Drug Profile 133
SLP-0901 - Drug Profile 134
SLP-0905 - Drug Profile 135
Small Molecule for Malaria and Bacterial Infections - Drug Profile 136
Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile 137
Small Molecules for Bacterial Infections and Lung Infection - Drug Profile 138
Small Molecules for Escherichia Coli Infections - Drug Profile 139
Small Molecules for Escherichia coli Infections - Drug Profile 140
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 141
Small Molecules to Inhibit 16S rRNA, Topoisomerases II and IV for Bacterial Infections - Drug Profile 142
Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections - Drug Profile 143
Small Molecules to Inhibit RecA for Bacterial Infections - Drug Profile 144
SPR-741 - Drug Profile 145
Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 146
Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 147
Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 148
Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections - Drug Profile 149
Synthetic Peptides for Escherichia Coli Infections - Drug Profile 150
TP-6076 - Drug Profile 151
VAR-10100 - Drug Profile 152
Escherichia coli Infections - Dormant Projects 153
Escherichia coli Infections - Discontinued Products 156
Escherichia coli Infections - Product Development Milestones 157
Featured News & Press Releases 157
Appendix 159
Methodology 159
Coverage 159
Secondary Research 159
Primary Research 159
Expert Panel Validation 159
Contact Us 159
Disclaimer 160

List of Tables
Number of Products under Development for Escherichia coli Infections, H2 2016 15
Number of Products under Development for Escherichia coli Infections - Comparative Analysis, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Number of Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Development, H2 2016 22
Products under Development by Companies, H2 2016 23
Products under Development by Companies, H2 2016 (Contd..1) 24
Products under Development by Companies, H2 2016 (Contd..2) 25
Products under Investigation by Universities/Institutes, H2 2016 26
Escherichia coli Infections - Pipeline by Adenium Biotech ApS, H2 2016 27
Escherichia coli Infections - Pipeline by Arsanis, Inc., H2 2016 28
Escherichia coli Infections - Pipeline by AstraZeneca Plc, H2 2016 29
Escherichia coli Infections - Pipeline by AvidBiotics Corp, H2 2016 30
Escherichia coli Infections - Pipeline by Cellceutix Corp, H2 2016 31
Escherichia coli Infections - Pipeline by Debiopharm International SA, H2 2016 32
Escherichia coli Infections - Pipeline by Emergent BioSolutions Inc, H2 2016 33
Escherichia coli Infections - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 34
Escherichia coli Infections - Pipeline by GangaGen Inc, H2 2016 35
Escherichia coli Infections - Pipeline by Hsiri Therapeutics LLC, H2 2016 36
Escherichia coli Infections - Pipeline by Johnson & Johnson, H2 2016 37
Escherichia coli Infections - Pipeline by Melinta Therapeutics Inc, H2 2016 38
Escherichia coli Infections - Pipeline by Merck & Co Inc, H2 2016 39
Escherichia coli Infections - Pipeline by Microbiotix Inc, H2 2016 40
Escherichia coli Infections - Pipeline by Nabriva Therapeutics AG, H2 2016 41
Escherichia coli Infections - Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 42
Escherichia coli Infections - Pipeline by Nosopharm SAS, H2 2016 43
Escherichia coli Infections - Pipeline by Novabiotics Ltd, H2 2016 44
Escherichia coli Infections - Pipeline by Omnia Molecular Ltd, H2 2016 45
Escherichia coli Infections - Pipeline by Paratek Pharmaceuticals Inc, H2 2016 46
Escherichia coli Infections - Pipeline by Pherecydes Pharma SA, H2 2016 47
Escherichia coli Infections - Pipeline by Phico Therapeutics Ltd, H2 2016 48
Escherichia coli Infections - Pipeline by Procarta Biosystems Limited, H2 2016 49
Escherichia coli Infections - Pipeline by Sealife PHARMA GMBH, H2 2016 50
Escherichia coli Infections - Pipeline by Sequoia Sciences Inc, H2 2016 51
Escherichia coli Infections - Pipeline by Soligenix Inc, H2 2016 52
Escherichia coli Infections - Pipeline by Syntiron LLC, H2 2016 53
Escherichia coli Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2016 54
Escherichia coli Infections - Pipeline by Varinel Inc, H2 2016 55
Assessment by Monotherapy Products, H2 2016 56
Number of Products by Stage and Target, H2 2016 58
Number of Products by Stage and Mechanism of Action, H2 2016 60
Number of Products by Stage and Route of Administration, H2 2016 62
Number of Products by Stage and Molecule Type, H2 2016 64
Escherichia coli Infections - Dormant Projects, H2 2016 158
Escherichia coli Infections - Dormant Projects (Contd..1), H2 2016 159
Escherichia coli Infections - Dormant Projects (Contd..2), H2 2016 160
Escherichia coli Infections - Discontinued Products, H2 2016 161

List of Figures
Number of Products under Development for Escherichia coli Infections, H2 2016 15
Number of Products under Development for Escherichia coli Infections - Comparative Analysis, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Products, H2 2016 22
Assessment by Monotherapy Products, H2 2016 56
Number of Products by Top 10 Targets, H2 2016 57
Number of Products by Stage and Top 10 Targets, H2 2016 57
Number of Products by Top 10 Mechanism of Actions, H2 2016 59
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 59
Number of Products by Routes of Administration, H2 2016 61
Number of Products by Stage and Routes of Administration, H2 2016 61
Number of Products by Top 10 Molecule Types, H2 2016 63
Number of Products by Stage and Top 10 Molecule Types, H2 2016 63

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *